XML 20 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Jun. 30, 2018
Dec. 31, 2017
Current Assets:    
Cash and cash equivalents $ 4,999 $ 5,421
Marketable Securities, Current 1,076 1,391
Receivables 5,559 6,300
Inventories 1,242 1,166
Prepaid expenses and other 998 576
Total Current Assets 13,874 14,854
Property, plant and equipment 5,080 5,001
Goodwill 6,683 6,863
Other intangible assets 1,090 1,210
Deferred income taxes 1,517 1,610
Marketable Securities, Noncurrent 2,117 2,480
Other assets 2,280 1,533
Total Assets 32,641 33,551
Current Liabilities:    
Short-term debt obligations 1,716 987
Accounts payable 1,873 2,248
Accrued liabilities 5,828 6,014
Deferred income 88 83
Income taxes payable 373 231
Total Current Liabilities 9,878 9,563
Deferred income 501 454
Income taxes payable 3,107 3,548
Pension and other liabilities 1,066 1,164
Long-term debt 5,671 6,975
Total Liabilities 20,223 21,704
Commitments and contingencies (Note 17)
Bristol-Myers Squibb Company Shareholders' Equity:    
Preferred stock 0 0
Common stock 221 221
Capital in excess of par value of stock 1,966 1,898
Accumulated other comprehensive loss (2,334) (2,289)
Retained earnings 32,044 31,160
Less cost of treasury stock (19,580) (19,249)
Total Bristol-Myers Squibb Company Shareholders' Equity 12,317 11,741
Noncontrolling interest 101 106
Total Equity 12,418 11,847
Total Liabilities and Equity $ 32,641 $ 33,551